| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2021 | Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study | Park K.; Haura E.B.; Leighl N.B.; Mitchell P.; Shu C.A.; Girard N.; Viteri S.; Han J.-Y.; Kim S.-W.; Lee C.K.; Sabari J.K.; Spira A.I.; Yang T.-Y.; Kim D.-W.; Lee K.H.; Sanborn R.E.; Trigo J.; Goto K.; Lee J.-S.; CHIH-HSIN YANG ; Govindan R.; Bauml J.M.; Garrido P.; Krebs M.G.; Reckamp K.L.; Xie J.; Curtin J.C.; Haddish-Berhane N.; Roshak A.; Millington D.; Lorenzini P.; Thayu M.; Knoblauch R.E.; Cho B.C. | Journal of Clinical Oncology | 187 | 157 | |
| 2020 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial | Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; CHIA-CHI LIN ; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. | Journal of Thoracic Oncology | 83 | 78 | |
| 2018 | Enhancer remodeling and MicroRNA alterations are associated with acquired resistance to ALK inhibitors | Yun M.R.; Lim S.M.; Kim S.-K.; Choi H.M.; Pyo K.-H.; Kim S.K.; Lee J.M.; Lee Y.W.; Choi J.W.; Kim H.R.; Hong M.H.; Haam K.; Huh N.; Kim J.-H.; Kim Y.S.; Shim H.S.; Soo R.A.; JIN-YUAN SHIH ; Chih-Hsin CHIH-HSIN YANG ; Kim M.; Cho B.C. | Cancer Research | 27 | 25 | |
| 2020 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials | Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; CHIA-CHI LIN ; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. | The Lancet Oncology | 250 | 218 | |
| 2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y. | The Lancet Oncology | 553 | 517 | |
| 2021 | Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study | Park K.; Jӓnne P.A.; Kim D.-W.; Han J.-Y.; Wu M.-F.; Lee J.-S.; Kang J.-H.; Lee D.H.; Cho B.C.; CHONG-JEN YU ; Pang Y.K.; Felip E.; Kim H.; Baek E.; Noh Y.S. | Cancer | 7 | 6 | |
| 2020 | Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies | Ahn M.-J.; Han J.-Y.; Kim D.-W.; Cho B.C.; Kang J.-H.; Kim S.-W.; CHIH-HSIN YANG ; Mitsudomi T.; Lee J.S. | Cancer Research and Treatment | 5 | 5 | |
| 2020 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study | Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG ; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. | The Lancet Oncology | 229 | 204 | |
| 2019 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Muro K.; Van Cutsem E.; Narita Y.; Pentheroudakis G.; Baba E.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH ; Kato K.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Nakajima T.E.; Shitara K.; Kawakami H.; Tsushima T.; Yoshino T.; Lordick F.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. | Annals of Oncology | 134 | 129 | |
| 2019 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Muro K.; Lordick F.; Tsushima T.; Pentheroudakis G.; Baba E.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Kato K.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH ; Nakajima T.E.; Shitara K.; Kawakami H.; Narita Y.; Yoshino T.; Van Cutsem E.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. | Annals of Oncology | 82 | 79 | |
| 2021 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors | Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; CHIA-CHI LIN | JTO Clinical and Research Reports | 3 | 0 | |
| 2019 | Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer | Yun M.R; Choi H.M; Lee Y.W; Joo H.S; Park C.W; Choi J.W; Kim D.H; Kang H.N; Pyo K.-H; Shin E.J; Shim H.S; Soo R.A; CHIH-HSIN YANG ; Lee S.S; Chang H; Kim M.H; Hong M.H; Kim H.R; Cho B.C. | EMBO Molecular Medicine | 30 | 29 | |
| 2020 | Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations | Paik P.K.; Felip E.; Veillon R.; Sakai H.; Cortot A.B.; Garassino M.C.; Mazieres J.; Viteri S.; Senellart H.; van Meerbeeck J.; Raskin J.; Reinmuth N.; Conte P.; Kowalski D.; Cho B.C.; Patel J.D.; Horn L.; Griesinger F.; Han J.-Y.; Kim Y.-C.; Chang G.-C.; Tsai C.-L.; CHIH-HSIN YANG ; Chen Y.-M.; Smit E.F.; van der Wekken A.J.; Kato T.; Juraeva D.; Stroh C.; Bruns R.; Straub J.; Johne A.; Scheele J.; Heymach J.V.; Le X. | New England Journal of Medicine | 341 | 303 | |
| 2020 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial | Wu Y.-L.; Cheng Y.; Zhou J.; Lu S.; Zhang Y.; Zhao J.; Kim D.-W.; Soo R.A.; Kim S.-W.; Pan H.; Chen Y.-M.; Chian C.-F.; Liu X.; Tan D.S.W.; Bruns R.; Straub J.; Johne A.; Scheele J.; Park K.; CHIH-HSIN YANG ; Liu Z.; Chen X.; Wang M.; Yu S.; Zhang H.; Fang J.; Li W.; Yang C.-H.; Chang G.-C.; Hsia T.-C.; Yang C.-T.; Wang C.-C.; Cho B.C.; Lee K.H.; Kim Y.-C.; An H.J.; Woo I.S.; Cho J.Y.; Shin S.W.; Lee J.-S.; Kim J.-H.; Yoo S.S.; Kato T.; Shinagawa N.; Tan S.W.D.; Ngo L.S.-M.; Ratnavelu K.; Ahmad A.R.; Liam C.K.; de Marinis F.; Tassone P.; Molla A.I.; Calles Blanco A.; Lazaro Quintela M.E.; Felip Font E.; Dingemans A.-M.; Bui L. | The Lancet Respiratory Medicine | 117 | 100 | |
| 2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | Okada M.; Kato K.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Matsumura Y.; Takazawa A.; Kitagawa Y. | Clinical Cancer Research | 10 | 9 | |
